Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia

Chest

Volumn 129, Issue 6, 2006, Pages 1407-1416

  Lewis, Bruce E ^a   Wallis, Diane E ^b   Hursting, Marcie J ^c   Levine, Robert L ^d   Leya, Fred ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Midwest Heart Specialists   (United States)

^c Clinical Science Consulting   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Argatroban; Heparin; Heparin induced thrombocytopenia; Platelets; Thrombocytopenia; Thrombosis

Indexed keywords

ARGATROBAN; THROMBIN INHIBITOR;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BODY WEIGHT; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENDER; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RISK; RISK REDUCTION; THROMBOCYTE COUNT; THROMBOSIS;

EID: 33745173460     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.6.1407     Document Type: Article

References (22)

1. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708
2. Shuster TA, Silliman WR, Coats RD, et al. Heparin-induced thrombocytopenia: twenty-nine years later. J Vasc Surg 2003; 38:1316-1322
3. Andreescu AC, Possidente C, Hsieh M, et al. Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia. Pharmacotherapy 2002; 20:974-80
4. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004; 164:361-369
5. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843
6. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856
7. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73-80
8. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100:587-593
9. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126:3118-3378
10. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: recommendations of the College of American Pathologists. Arch Pathol Lab Med 2002; 126:1415-1423
11. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003; 110:73-82
12. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004; 76:240-244
13. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004; 32:976-980
14. Kelton JG, Hursting MJ, Lewis BE. The predictors of clinical outcome in patients with heparin-induced thrombocytopenia [abstract]. J Thromb Haemost 2003; 1(suppl):OC020
15. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. Thromb Haemost 2005; 94:132-135
16. Levine RL, Hursting MJ, Drexler A, et al. Heparin-induced thrombocytopenia in the emergency department. Ann Emerg Med 2004; 44:511-515
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
18. Cox DR. Regression models and life tables. J Royal Stat Soc Series B 1972; 34:187-220
19. Francis J, Drexler A. Frequency of heparin-platelet factor 4 antibodies in patients presenting to the emergency room with symptoms of thrombosis [abstract]. J Thromb Haemost 2003; 1(suppl 1):P1147
20. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002; 57:177-184
21. Haas S. Heparin-induced thrombocytopenia (HIT) type II; a clinically heterogeneous hypercoagulable state requiring prompt intervention. Thromb Haemost 2004; Suppl 5:42-45
22. Warkentin TE, Sigounin CS. Gender and risk of immune heparin-induced thrombocytopenia [abstract]. Blood 2002; 100:17a